These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4145 related items for PubMed ID: 27341514

  • 1. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM, Kemp TJ, Dharmani-Khan P, Lewis V, Tripathi G, Rajalingam R, Daly A, Berka N, Storek J, Masood Khan F.
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [Abstract] [Full Text] [Related]

  • 2. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U, Dalva K, Gungor F, Ustun C, Beksac M.
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [Abstract] [Full Text] [Related]

  • 3. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H, Bao X, Wu X, Tang X, Wang M, Wu D, He J.
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [Abstract] [Full Text] [Related]

  • 4. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS, Kwak DH, Jeon YW, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Min WS, Lee JW.
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [Abstract] [Full Text] [Related]

  • 5. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
    Rangarajan HG, Pereira MSF, Brazauskas R, St Martin A, Kussman A, Elmas E, Verneris MR, Gadalla SM, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Lee DA.
    Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
    [Abstract] [Full Text] [Related]

  • 6. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, Ko SH, Seol M, Lee YS, Kang YA, Jeon M, Baek S, Kang YL, Kim SH, Yun SC, Kim H, Jo JC, Choi Y, Joo YD, Lim SN.
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
    Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G, ATG-Fresenius Trial Group.
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1716-26. PubMed ID: 22713691
    [Abstract] [Full Text] [Related]

  • 8. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Ravinet A, Cabrespine A, Socié G, Milpied N, Yakoub Agha I, Nguyen S, Michallet M, Menard AL, Maillard N, Mohty M, Suarez F, Huynh A, Marchand T, Deteix C, Cassuto JP, Maury S, Chevallier P, Reman O, Peffault de Latour R, Bay JO.
    Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
    [Abstract] [Full Text] [Related]

  • 9. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
    Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Cereb N, Haagenson MD, Spellman SR, Lee SJ, Guethlein LA, Parham P, Miller JS, Cooley SA.
    Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
    [Abstract] [Full Text] [Related]

  • 10. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano AM, Messina G, Bethge W, Herrera P, Sureda A, Carella AM, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N.
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [Abstract] [Full Text] [Related]

  • 11. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
    Clausen J, Kircher B, Auberger J, Schumacher P, Ulmer H, Hetzenauer G, Wolf D, Gastl G, Nachbaur D.
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
    [Abstract] [Full Text] [Related]

  • 12. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT, D'Aveni-Piney M, Labopin M, Hamladji RM, Sanz MA, Blaise D, Ozdogu H, Daguindeau E, Richard C, Santarone S, Irrera G, Yakoub-Agha I, Yeshurun M, Diez-Martin JL, Mohty M, Savani BN, Nagler A.
    J Hematol Oncol; 2017 Jan 24; 10(1):31. PubMed ID: 28118857
    [Abstract] [Full Text] [Related]

  • 13. KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A.
    Wu X, Yao Y, Bao X, Zhou H, Tang X, Han Y, Ma X, Liu Y, Chen J, Zhou H, Jing S, Gu B, Xu Y, Sun A, He J, Wu D.
    Biol Blood Marrow Transplant; 2016 Feb 24; 22(2):220-225. PubMed ID: 26476204
    [Abstract] [Full Text] [Related]

  • 14. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A, Mallick R, Huebsch L, Allan D, Atkins H, Anstee G, Sabloff M, Scrivens N, Maze D, Bredeson C, Kekre N.
    Biol Blood Marrow Transplant; 2017 Dec 24; 23(12):2096-2101. PubMed ID: 28821454
    [Abstract] [Full Text] [Related]

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 24; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 16. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
    Liang ZY, Ren HY, Cen XN, Qiu ZX, Wang LH, Ou JP, Li Y, Wang MJ, Wang WS, Xu WL, Dong YJ, Yin Y, Sun YH.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb 24; 21(1):155-60. PubMed ID: 23484711
    [Abstract] [Full Text] [Related]

  • 17. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
    Hoseinian SA, Jafari D, Mahmoodi M, Alimoghaddam K, Ostadali M, Talebzadeh Bonakdar A, Foma AM, Yekaninejad MS, Amirzargar AA.
    Turk J Med Sci; 2018 Aug 16; 48(4):794-804. PubMed ID: 30119155
    [Abstract] [Full Text] [Related]

  • 18. The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor hematopoietic stem cell transplantation for myeloid malignancies.
    Wang H, He Y, Zhai WJ, Wang M, Zhou Z, Zhao YX, Feng SZ, Han MZ.
    Swiss Med Wkly; 2013 Aug 16; 143():w13717. PubMed ID: 23299929
    [Abstract] [Full Text] [Related]

  • 19. Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.
    Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Trachtenberg E, Haagenson MD, Spellman SR, Ladner M, Guethlein LA, Parham P, Miller JS, Cooley SA.
    Biol Blood Marrow Transplant; 2016 Sep 16; 22(9):1602-1607. PubMed ID: 27220262
    [Abstract] [Full Text] [Related]

  • 20. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.
    Zhao XY, Huang XJ, Liu KY, Xu LP, Liu DH.
    Eur J Haematol; 2007 Apr 16; 78(4):338-46. PubMed ID: 17378893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 208.